VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?

CHICAGO – Combining the immunotherapy antibodies nivolumab and ipilimumab induced more robust responses in untreated advanced melanoma when used together than as single agents, according to phase III...